Efavirenz+Emtricitabine+Tenofovir Disoproxil Fumarate

Description

This page contains brief details about the drug efavirenz,emtricitabine,tenofovir disoproxil fumarate, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Efavirenz, Emtricitabine and Tenofovir disoproxil Fumarate is a complete regimen consisting of antiviral medications, which was approved for its medical use on 12th July 2006.

Mechanism of Action of Efavirenz+Emtricitabine+Tenofovir Disoproxil Fumarate

Efavirenz, Emtricitabine and Tenofovir disoproxil Fumarate Tablet is a combination of non-nucleoside reverse transcriptase inhibitor, nucleoside reverse transcriptase inhibitor and nucleotide reverse transcriptase inhibitors. It works by increasing the number of CD4 T cells and stimulates the immune system to fight against infections. Thereby, it reduces the viral load of HIV in the blood and decreases the severity of HIV infection.

Uses of Efavirenz+Emtricitabine+Tenofovir Disoproxil Fumarate

Efavirenz, Emtricitabine and Tenofovir disoproxil Fumarate is indicated as a complete regimen to treat human immunodeficiency virus infection in adults and paediatric patients older than 12 years of age.

Efavirenz+Emtricitabine+Tenofovir Disoproxil Fumarate Dosage available Efavirenz, Emtricitabine and Tenofovir disoproxil fumarate is available as film coated tablets consisting of 600mg of Efavirenz, 200mg of Emtricitabine and 300mg of Tenofovir disoproxil fumarate. The usual recommended dosage of this combination regimen is one tablet every day, preferably at bedtime.